Once-weekly insulin icodec compared with daily basal insulin analogues in type 2 diabetes: Participant-level meta-analysis of the ONWARDS 1-5 trials
EndocrinologiaSobre o estudo
- Desenho
- Metanálise
- Nível de evidência
- 1 · Evidência consolidada
- Revista
- Diabetes, obesity & metabolism
- Publicado em
- 1 jul 2024
- Citações
- 28
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Once-weekly insulin icodec compared with daily basal insulin analogues in type 2 diabetes: Participant-level meta-analysis of the ONWARDS 1-5 trials
Harpreet S Bajaj, Björg Ásbjörnsdóttir, Tanvir J Bari, Kamilla Begtrup, Tina Vilsbøll, Julio Rosenstock
Descritores MeSH
- Insulin, Long-Acting
- Diabetes Mellitus, Type 2
- Glycated Hemoglobin
- Hypoglycemia
- Hypoglycemic Agents
- Humans
- Clinical Trials, Phase III as Topic
- Insulin Glargine
- Incidence
- Blood Glucose
Veja também
Estudos relacionados
- Thrice-Weekly Insulin Degludec Versus Once-Daily Insulin Glargine in Insulin-Naïve Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis
- Efficacy and Safety of Once-Weekly Semaglutide 2.0 mg as an Add-On to Dose-Reduced Insulin Glargine versus Dose-Titrated Insulin Glargine in People With Type 2 Diabetes and Overweight (SUSTAIN OPTIMIZE)
- Impact of Time of Injection on the Efficacy and Safety of iGlarLixi Versus IDegAsp in Chinese People With Type 2 Diabetes: Exploratory Analysis of the Soli-D Study
- Efficacy and safety of once-weekly insulin icodec versus once-daily basal insulin in Japanese individuals with type 2 diabetes: A subgroup analysis of the ONWARDS 1, 2 and 4 trials